NCT01106352View on ClinicalTrials.gov

A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Bone MetastasesCastration-Resistant Prostate Cancer
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.

DRUG

Docetaxel

Docetaxel (75 mg/m\^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m\^2 is allowed as per the approved docetaxel label.

Trial Locations (7)

10065

New York

21287

Baltimore

60201

Evanston

94115

San Francisco

94805

Villejuif

98109

Seattle

02115-6013

Boston

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01106352 - A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | Biotech Hunter | Biotech Hunter